From left: Dr. Vaithilingaraja Arumugaswami and Dr. Robert Damoiseaux.
Researchers from UCLA are part of a collaboration of scientists from several universities studying the potential that the anti-cancer drug berzosertib could be effective in treating or preventing SARS-CoV-2, the virus that causes COVID-19.
Other co-authors are from UCLA, Cedars-Sinai Medical Center, UC Irvine, University of Delaware, the Leibniz Institute for Experimental Virology in Germany, Heidelberg University in Germany, and Scripps Research Institute.
Read on in the UCLA press release.
This research was supported in part by the Broad Stem Cell Research Center, the UCLA David Geffen School of Medicine, UCLA CTSI (using funds obtained through the UCLA Oversight COVID-19 Research Committee) and more.